- Home
- DGICB vs PHAT Comparison
DGICB vs PHAT Comparison
Compare DGICB & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGICB
- PHAT
- Stock Information
- Founded
- DGICB 1986
- PHAT 2018
- Country
- DGICB United States
- PHAT United States
- Employees
- DGICB N/A
- PHAT N/A
- Industry
- DGICB Property-Casualty Insurers
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- DGICB Finance
- PHAT Health Care
- Exchange
- DGICB Nasdaq
- PHAT Nasdaq
- Market Cap
- DGICB 504.0M
- PHAT 465.0M
- IPO Year
- DGICB N/A
- PHAT 2019
- Fundamental
- Price
- DGICB $14.88
- PHAT $6.96
- Analyst Decision
- DGICB
- PHAT Strong Buy
- Analyst Count
- DGICB 0
- PHAT 4
- Target Price
- DGICB N/A
- PHAT $23.00
- AVG Volume (30 Days)
- DGICB 783.0
- PHAT 971.9K
- Earning Date
- DGICB 02-20-2025
- PHAT 03-06-2025
- Dividend Yield
- DGICB 4.17%
- PHAT N/A
- EPS Growth
- DGICB 148.60
- PHAT N/A
- EPS
- DGICB 0.74
- PHAT N/A
- Revenue
- DGICB $979,119,004.00
- PHAT $26,270,000.00
- Revenue This Year
- DGICB N/A
- PHAT $7,622.43
- Revenue Next Year
- DGICB $5.78
- PHAT $236.87
- P/E Ratio
- DGICB $19.93
- PHAT N/A
- Revenue Growth
- DGICB 7.44
- PHAT N/A
- 52 Week Low
- DGICB $10.75
- PHAT $6.07
- 52 Week High
- DGICB $16.81
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- DGICB 57.56
- PHAT 37.02
- Support Level
- DGICB $13.90
- PHAT $6.36
- Resistance Level
- DGICB $14.20
- PHAT $7.20
- Average True Range (ATR)
- DGICB 0.30
- PHAT 0.48
- MACD
- DGICB 0.00
- PHAT 0.08
- Stochastic Oscillator
- DGICB 63.08
- PHAT 30.48
About DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.